top of page

Harvard Wyss Institute’s eRapid multiplexed biosensor technology licensed to Stata DX

Benjamin Boettner

22 Jun 2022

The startup will develop and commercialize cost-effective, highly sensitive and specific point-of-care diagnostics, applying a novel electrochemical sensor platform created at the Wyss Institute

(BOSTON) — Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announced that the Wyss Institute’s affinity-based, multiplexed, electrochemical sensing technology, eRapid, has been licensed to the startup. The license, coordinated by Harvard’s Office of Technology Development (OTD), grants Stata DX exclusive worldwide access to the eRapid technology in the fields of neurological, cardiovascular, and renal diseases

bottom of page